396 related articles for article (PubMed ID: 9039343)
41. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
42. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
J Neural Transm Gen Sect; 1995; 99(1-3):187-93. PubMed ID: 8579804
[TBL] [Abstract][Full Text] [Related]
43. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
44. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma.
Nobels FR; de Herder WW; van den Brink WM; Kwekkeboom DJ; Hofland LJ; Zuyderwijk J; de Jong FH; Lamberts SW
Eur J Endocrinol; 2000 Nov; 143(5):615-21. PubMed ID: 11078985
[TBL] [Abstract][Full Text] [Related]
45. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
Guido R; Valenti S; Foppiani L; De Martini D; Cossu M; Giusti M
J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
[TBL] [Abstract][Full Text] [Related]
46. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
47. Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study.
Mo C; Chen H; Xu J; Guo Y; Wang Y; Li Z; Tong T; Gui S; Zhong L
Endocr Pract; 2024 May; 30(5):441-449. PubMed ID: 38307455
[TBL] [Abstract][Full Text] [Related]
48. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
[TBL] [Abstract][Full Text] [Related]
49. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
[TBL] [Abstract][Full Text] [Related]
50. MR imaging of pituitary adenomas treated with the prolactin inhibitor quinagolide.
Ilkko E; Tikkakoski T; Salmela P; Pyhtinen J; Kurunlahti M
Acta Radiol; 2002 Mar; 43(2):125-9. PubMed ID: 12010287
[TBL] [Abstract][Full Text] [Related]
51. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
52. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
[TBL] [Abstract][Full Text] [Related]
53. D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.
Schlösser R; Schlegel S
J Neural Transm Gen Sect; 1995; 99(1-3):173-85. PubMed ID: 8579803
[TBL] [Abstract][Full Text] [Related]
54. Evidence for dopamine-related and TRH-related pituitary TSH and PRL pools in patients with prolactinoma.
Hanew K; Utsumi A; Sugawara A; Shimizu Y; Yoshinaga K
Acta Endocrinol (Copenh); 1991 May; 124(5):545-52. PubMed ID: 1903012
[TBL] [Abstract][Full Text] [Related]
55. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.
Toyama H; Ichise M; Ballinger JR; Fornazzari L; Kirsh JC
Ann Nucl Med; 1993 Feb; 7(1):29-38. PubMed ID: 8461237
[TBL] [Abstract][Full Text] [Related]
56. Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas.
Faccenda E; Melmed S; Bevan JS; Eidne KA
Clin Endocrinol (Oxf); 1996 Mar; 44(3):341-7. PubMed ID: 8729534
[TBL] [Abstract][Full Text] [Related]
57. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
58. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours.
Benker G; Gieshoff B; Freundlieb O; Windeck R; Schulte HM; Lancranjan I; Reinwein D
Clin Endocrinol (Oxf); 1986 May; 24(5):505-13. PubMed ID: 3791649
[TBL] [Abstract][Full Text] [Related]
59. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
60. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
Schwarz J; Oertel WH; Tatsch K
J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
